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Title: Economic evaluation of prescribing conventional and newer oral 
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Abstract 
Introduction: Anticoagulants refer to a variety of agents that inhibit one or more steps in the 
coagulation cascade. Generally, clinical conditions that require the prescribing of an oral 
anticoagulant increase in frequency with age. However, a major challenge of anticoagulation 
use among older patients is that this group of patients also experience the highest bleeding 
risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or 
newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted.  
 
Areas covered:  A review of articles that evaluated the cost of prescribing conventional (e.g. 
vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa 
inhibitors) in older adults.  
 
Expert commentary: While the use of NOACs significantly increases the cost of the initial 
treatment for thromboembolic disorders, they are still considered cost-effective relative to 
warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum 
anticoagulation with warfarin can be achieved by providing specialised care; clinics managed 
by pharmacists have been shown to be cost-effective relative to usual care. There are 
suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining 
more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.  
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1. Introduction 
Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation 
cascade [1]. They can be classified according to their mechanism of action, including direct 
enzymatic inhibition, indirect inhibition by binding to antithrombin and antagonism of vitamin 
K-dependent factors, by preventing their synthesis in the liver and/or modification of their 
calcium-binding properties [1]. The list of anticoagulants which are licenced for use include 
unfractionated heparin, low molecular weight heparins, fondaparinux, vitamin K antagonists, 
direct thrombin inhibitors and direct factor Xa inhibitors.  
Historically, vitamin K antagonists were the only anticoagulants widely available for human 
use. Major concerns with the use of vitamin K antagonists include the risk of bleeding 
complications, narrow therapeutic index, variability of dose-response, numerous interactions 
with other medications, as well as the requirement for frequent monitoring, with associated 
costs and burdens [2]. Patients receiving vitamin K antagonists should be aware of 
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interactions with food and alcohol. The consumption of large amounts of some specific food 
(e.g. rich in vitamin K or cranberries) can lead to over or under coagulation that can increase 
the risk of thromboembolism or bleeding. In view of these concerns, safer and more 
convenient anticoagulants have been sought. 
The direct thrombin inhibitors and direct factor Xa inhibitors have been introduced into the 
market as viable and promising alternatives to warfarin. As their name implies, direct 
thrombin inhibitors bind to the active site of the thrombin enzyme [3]. The only oral direct 
thrombin inhibitor available for clinical use is dabigatran etexilate. Another oral agent, 
ximelagatran, has been withdrawn from the market in 2006 because of concerns 
surrounding associated hepatotoxicity and cardiovascular events [4]. Direct factor Xa 
inhibitors inhibit the active site of factor Xa reversibly without the need to bind to antithrombin, 
hence their name as direct factor Xa inhibitors [5]. Oral direct factor Xa inhibitors available 
for clinical use include rivaroxaban, apixaban, and edoxaban.  
Older adults constitute a patient population who are often viewed as frail and immobile with 
multiple acute and/or chronic medical disorders and who are often taking multiple 
medications. The highly prevalent risk factors associated with thromboembolism and the 
presence of cardiac and thrombotic disorders in older adults necessitate the use of 
anticoagulant therapy either on a short- or a long-term basis. Some of these conditions also 
are more prevalent in older adults; non-valvular atrial fibrillation, for instance, increases from 
0.5% between 50 and 59 years to approximately 9% between 80 and 89 years of age [6]. 
Similarly, according to the Worcester DVT Study in United States, venous thromboembolism, 
which encompasses both deep vein thrombosis and/or pulmonary embolism, also increases 
exponentially with advancing age, rising from an annual incidence of approximately 
30/100,000 at age of 40 years to 90/100,000 at age of 60 years and 260/100,000 at age of 
80 years [7].  
Despite the clear need and benefit of anticoagulants in the older population, there are 
important concerns pertaining to the appropriateness and safety of these agents. Older 
adults are inherently more vulnerable to anticoagulant-associated bleeding and may be 
taking multiple medications that interact and thus mandate extra pharmacovigilance [8]. 
However, clinical data on older adults is limited, and they are often underrepresented in 
randomised controlled trials, for reasons such as frailty or renal function [9].  
 
2. Cost evaluation of prescribing oral anticoagulants 
2.1. Vitamin K antagonists 
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The usual international normalised target (INR) of 2.0–3.0 which optimises the efficacy and 
safety of warfarin therapy is difficult to achieve consistently especially among older adult 
patients due to prevalence of factors such as polypharmacy and comorbidity as discussed in 
the previous section [10-11]. Even in presence of simple, safe, and accurate warfarin 
regimen [12], maintaining people on warfarin therapy is a complex process and may lead to 
incompliance and possible instability of anticoagulation levels [13]. Therefore, warfarin 
therapy requires regular monitoring of the INR, regardless of age, to ensure its effectiveness 
and safety. In the average patient, the INR is monitored every 2-4 weeks and such dedicated 
monitoring comes at a cost.  
To date, there is only one systematic review investigating the costs involved in monitoring of 
the INR during treatment with vitamin K antagonists [14]. This review included 29 studies 
from ten countries; the majority of the studies were conducted in the United Kingdom and the 
United States. As reported in the systematic review, the cost of conducting one INR test 
ranged from USD 6.19 for point-of-care testing in a primary care clinic, to USD 145.70 for a 
home visit with laboratory testing. However, the cost of performing one INR test differed with 
the number of cost categories included in these studies. For example, the study that 
included the most detailed cost categories, such as staff time, equipment, and consumables, 
among others, reported higher costs (USD 145.57) than studies that involved only few cost 
categories (USD 11.75). The costs associated with INR monitoring also differed according to 
the settings for monitoring. INR monitoring that was performed in specialist hospital clinics 
reported costs that ranged from USD 11.75 to USD 45.57. On the other hand, for INR 
monitoring that was conducted in general practice, the costs ranged from USD 24.19 to USD 
88.76. Performance of INR monitoring at a practice-based clinic observed a range of costs 
from USD 6.19 to USD 83.36. The costs reported with home monitoring varied from USD 
8.42 to USD 145.57. In addition, the costs also depended on the method of monitoring. For 
laboratory testing with hospital-based care, the cost of one INR test varied from USD 11.75 
to USD 45.57, while those for laboratory testing with general practice-based care varied from 
USD 24.19 to USD 145.57. For INR monitoring that utilised a computerized decision support 
system, the reported cost for one INR monitoring ranged from USD 6.19 to USD 83.36 [14]. 
With the introduction of patient monitoring devices, now INR can be determined by the 
patients, thus reducing the cost of INR monitoring. 
 
Older patients are at a heightened risk of developing anticoagulant-related bleeding events, 
where the most fearful events being intracranial haemorrhage and gastrointestinal bleeding. 
The costs of managing and treating these bleeding events are high [15,16]. In 2010, one 
study by Kim and colleagues described the hospitalisation costs for bleeding events due to 
4 
 
warfarin therapy and focused on the older community-dwelling adults [15]. The study was of 
substantial size, with 2346 subjects over the age of 65 enrolled. It was reported that the 
mean cost of a warfarin-related hospitalisation was USD 10,819 (standard deviation [SD] = 
USD 11,536) with a mean length of hospital stay of 7.8 days (SD=7.1 days). When the entire 
cohort was factored in, warfarin-related bleeding led to an increased cost of hospitalisation of 
USD 508.30 per warfarin user on average. Ghate et al. assessed health care costs related to 
warfarin-associated intracranial haemorrhage and gastrointestinal bleeding in 48,069 
patients aged 18 years or older with newly diagnosed atrial fibrillation [16]. The mean 
unadjusted all-cause health care cost per patient within 12 months after initiating warfarin 
therapy reached USD 41,903 (SD = USD56,654) for patients who experienced at least one 
event of intracranial haemorrhage. The cost was USD 40,586 (SD = USD 65,164) for 
patients who experienced at least one event of major gastrointestinal bleeding, and USD 
24,347 (SD = USD 56,488) for patients who experienced at least one event of minor 
gastrointestinal bleeding. After adjustment for patient characteristics, the mean all-cause 
annual costs totalled USD 42,574 for patients who experienced at least one event of 
intracranial haemorrhage, USD 36,571 for patients who experienced at least one event of 
major gastrointestinal bleeding, and USD 22,824 for patients who experienced at least one 
event of minor gastrointestinal bleeding. Observed higher costs in patients with major 
gastrointestinal or intracranial bleeding were primarily due to higher utilisation of inpatient 
service, as manifested by higher all-cause mean inpatient costs, while patients with minor GI 
bleeding utilised significantly more outpatient health care services. However, this study did 
not focus on older adults [16].  
2.2. Novel Oral Anticoagulants 
According to current literature, the NOACs are at least as effective as adjusted dose warfarin 
therapy (INR of 2.0 to 3.0), when used for FDA-approved indications [17-22]. The clinical 
trials (Phase III) for NOACs demonstrated that both dabigatran (RE-LY) and apixaban 
(ARISTOTLE) were more efficacious at preventing stroke in nonvalvular atrial fibrillation than 
warfarin, while rivaroxaban (ROCKET-AF) was shown to be non-inferior to warfarin [17-19]. 
At least three meta-analyses have pooled the results from the RE-LY (dabigatran), 
ARISTOTLE (apixaban), and ROCKET AF (rivaroxaban) trials and reached similar 
conclusions, where significant reduction of stroke or systemic embolism as well as all-cause 
mortality were demonstrated as compared to warfarin [20-22]. There are at least two meta-
analyses that pooled the results of randomized trials of NOACs for efficacy and bleeding 
outcomes relative to vitamin K antagonists among older participants (aged ≥75 years). In the 
first meta-analysis with ten randomised controlled trials and 25,031 older participants 
included, it was reported that the risk of major or clinically relevant bleeding was not 
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significantly different between NOACs and conventional therapy (warfarin, low-molecular-
weight heparin, low-molecular-weight heparin followed by vitamin K antagonists) in older 
adults [23]. NOACs were also associated with equal or greater efficacy in both preventions 
of stroke or systemic embolism in atrial fibrillation as well as venous thromboembolism or 
venous thromboembolism-related death than conventional therapy in older adults. In a 
separate meta-analysis, which included 11 randomised controlled trials with 31,418 older 
participants, significant reduction in the risk of major bleeding was observed when compared 
to vitamin K antagonist for apixaban, edoxaban 60 mg and 30 mg, whereas no significant 
difference was observed for dabigatran 150 mg and 110 mg as well as rivaroxaban.  Each 
NOAC was also proven to be at least as effective as VKA when used in older patients, both 
in reduction of the risk of stroke and systemic embolism in atrial fibrillation as well as the risk 
of recurrent venous thromboembolism [24]. Due to short half-lives of NOACs, a lack of 
adherence to prescribed NOACs therapy may possibly result in a greater risk for 
thromboembolic events and decline in therapeutic effect following a missed dose [25]. The 
decline in therapeutic effect following a single missed dose of the NOACs could put the 
patients at risk for a thromboembolic event, subsequently leading to added costs to the 
patient [26]. On the other hand, warfarin takes an average of 4-5 days for therapeutic activity 
to return to baseline following discontinuation [26] 
In a similar manner to warfarin, adverse events like bleeding also contribute significantly to 
the overall cost of NOACs, especially gastrointestinal bleeding and intracranial haemorrhage. 
However, all the NOACs demonstrated high relative reduction in the risk of intracranial 
haemorrhage, which is the bleeding event associated with the highest cost [17-19]. Despite 
showing important advantage in terms of the rates of intracranial haemorrhage, dabigatran is 
associated with an increased risk of dyspepsia and gastrointestinal bleeding by as much as 
10%, which may increase adverse event-related cost [25].   
Although NOACs are reported to not require therapeutic monitoring, there are still some 
laboratory parameters that must be monitored to ensure safe therapy [27]. Regardless of the 
type of anticoagulant prescribed, patients should have a complete blood count every 6 
months to monitor for bleeding [27]. In addition, due to the hepatic and renal routes of 
elimination of NOACs, renal and hepatic function monitoring is recommended as clinically 
indicated which is generally once a year, depending on the agent [27].  
3. Cost-effective approaches in prescribing oral anticoagulants in older adults 
3.1. Prescribing of NOACs 
A recently published systematic review, which included 54 studies from a vast number of 
countries, examined the cost-effectiveness of non-vitamin K antagonists for the prevention of 
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stroke in non-valvular atrial fibrillation [28]. The studies generally simulated cohorts of older 
adult patients, aged from 70 to 75 years, and their cost data were mostly reported in the 
payer’s perspective. As expected for atrial fibrillation treatment, a long-term perspective was 
adopted for almost all of the included studies. When only the studies with a lifetime 
perspective were taken into consideration, the mean incremental quality-adjusted life year 
(QALY) of NOACs was 0.310. An increase in overall health-care costs was observed with 
the use of NOACs in majority of the studies, but the incremental cost-effectiveness ratio 
(ICER) was mostly below the reported willingness-to-pay threshold, indicating their cost-
effectiveness. Additionally, in all the analyses that compared different dabigatran dosages to 
vitamin K antagonist, dabigatran 150 mg twice daily and sequential dabigatran dosage 
approach (150 mg twice daily until the age of 80 and 110 mg twice daily thereafter) showed 
a better ICER with respect to dabigatran 110 mg twice daily, with dominance reported in 
majority of the studies. Moreover, among all the studies that compared more than one 
NOAC to vitamin K antagonist, apixaban generally performed better than the other NOACs, 
in which apixaban showed a more favourable ICER with respect to dabigatran 150 mg twice 
daily, edoxaban, and rivaroxaban, and was found dominant on sequential dabigatran dosage 
approach, dabigatran 150 mg twice daily and rivaroxaban [28]. 
In another recently published study (not included in the aforementioned review), the authors 
analysed the comparative cost-effectiveness of warfarin and NOACs for the prevention of 
stroke, specifically in older patients with atrial fibrillation [29]. To simulate more closely the 
real-world settings, the treatment effects were derived from a comprehensive network meta-
analysis of oral antithrombotics for the prevention of stroke in atrial fibrillation that included 
not only data from randomised controlled trials, but also data from observational studies. The 
authors constructed a life-time Markov model, consisting of 10 health states. The cost 
categories included treatment and monitoring cost as well as acute and long-term cost of 
managing clinical events. Local survey and analysis as well as data from published literature 
were used to correlate the 10 health states and calculate utility values. It was noted in the 
study that all NOACs, with the exception of dabigatran 110 mg twice daily, were associated 
with incremental cost-effectiveness ratios of USD 24,476 to USD 41,448, which were below 
the recommended cost-effectiveness threshold of USD 49,700 by the World Health 
Organisation. Threshold analysis reveal that the reported cost-effectiveness was mainly 
driven by treatment effectiveness of NOACs, in which the reduced risk of ischaemic stroke 
and intracranial haemorrhage associated with the use of NOACs translated into a lower cost 
of managing stroke and bleeding events in long term with more QALYs gained, in spite of 
higher drug acquisition costs of NOACs [29]. 
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3.2. Pharmacist-participated warfarin therapy management 
The cost-effectiveness of pharmacist-participated warfarin therapy management was 
evaluated in a systematic review of four studies, conducted in the United States and through 
Asia [30]. All of the included studies compared monitoring services provided by pharmacists 
or a combination of pharmacists and physicians, compared with usual care. They employed 
a Markov model with a long-term time horizon for repeated health states that allowed 
recurrence of health outcomes related to bleeding and embolism, with the different types or 
levels of bleeding. The efficacy or effectiveness of pharmacist-participated warfarin therapy 
management was estimated through data derived from trials on the efficacy to control 
patients’ INRs in the therapeutic range or rates of bleeding and thromboembolic events. 
While there are two studies which reported that pharmacist-participated warfarin therapy 
management was more expensive than usual care, all included studies concluded that 
pharmacist-participated warfarin therapy management was either cost-saving or cost-
effective, which was confirmed by multivariate probabilistic sensitivity analyses. To illustrate, 
in one of the included studies that focused on older patients at the age of 70 or older with 
atrial fibrillation who were at high risk of stroke, the authors reported that pharmacist-
participated warfarin therapy management was less costly compared to the usual care with 
an incremental QALYs gained per person of 0.058 per 10 years, reaching to a conclusion 
that the pharmacist-participated warfarin therapy management was cost-saving [31]. 
3.3. Pharmacogenetic-guided dosing of warfarin 
There are at least three randomised controlled trials of pharmacogenetic-guided dosing of 
warfarin published to date with the main outcome measure of percentage time spent in 
therapeutic INR range [32-34]. Although hard clinical outcomes such as bleeding and stroke 
cannot be reported due to studies being underpowered, percentage time spent in 
therapeutic INR range is a suitable proxy measure since a 6-10% improvement in 
percentage time spent in therapeutic INR range would result in clinically significant 
improvement in the risk of bleeding and stroke [35,36]. One of the trials demonstrated that 
pharmacogenetic-guided dosing increased the percentage time spent in therapeutic INR 
range in the initial 12 weeks of therapy by 7.0 percentage points compared to standard 
dosing [33].  
Nevertheless, genotyping would incur additional costs, which therefore necessitates cost-
effective analysis prior to routine implementation in clinical practice. The evidence to date is 
not sufficient to conclude the cost-effectiveness of genotype-guided dosing strategy in 
comparison to normal dosing strategy. This is illustrated in a systematic review by Verhoef et 
al. which included nine economic studies of pharmacogenetic-guided dosing of warfarin 
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derivatives published before the year of 2010, which were predominantly conducted in the 
United States [37]. Most of the studies compared pharmacogenetic-guided dosing against 
standard dosing and reported the number of bleeding events (or adverse events) avoided 
and QALYs gained as outcome measures. In addition, the majority of the studies evaluated 
the costs from a healthcare sector perspective and employed a time horizon of 12 months. 
The cost of CYP2C9 genotyping ranged from US$67 to US$350, while the cost of 
genotyping both VKORC1 and CYP2C9 ranged from US$200 to US$575. More than half of 
the included studies observed additional healthcare costs with pharmacogenetic-guided 
dosing strategy. The costs per adverse event avoided varied from being dominant to 
US$170,792, while the cost per QALY gained varied from US$171,750 to US$347,059. Due 
to heterogeneity in the results of the included economic evaluations, no conclusive remarks 
could be made regarding the cost–effectiveness of this strategy [37].  
In a recently published study, which evaluated the cost-effectiveness of the 
pharmacogenetic-guided dosing of warfarin, the authors constructed a Markov model to 
compare the incidence of adverse events and QALYs between pharmacogenetic-guided 
dosing and standard dosing over a lifetime time horizon among patients with atrial fibrillation 
in United Kingdom and Sweden [38]. This study had less uncertainty around the estimated 
effectiveness relative to previous studies because this is the only economic study to date 
that employed the treatment effect from a randomised controlled trial that was appropriately 
powered, namely, percentage time spent in therapeutic INR range, to populate the 
constructed Markov model. The authors then extrapolated the treatment effect to the 
incidence of stroke and bleeding events. Data on costs, utilities and probabilities were 
obtained from multiple studies within the literature. It was reported in the study that 
genotype-guided strategy reduced the risk of developing bleeding events by 0.18% and 0.2% 
in the United Kingdom and in Sweden, respectively. A reduction in the risk of 
thromboembolic events by 0.04% was noted in both countries. In the United Kingdom, 
pharmacogenetic-guided strategy caused an increase in lifetime costs of £26 and QALYs of 
0.0039, resulting in an ICER of £6 702 per QALY gained, which is below the cost-
effectiveness threshold range of £20 000–£30 000 per QALY gained. In Sweden, additional 
costs incurred and QALYs gained were 382 SEK and 0.0015, respectively, with an ICER of 
253 848 SEK per QALY gained, which is below the cost-effectiveness threshold of 500 000 
SEK [38]. 
4. Expert commentary 
While the use of NOACs significantly increases the cost of pharmacological treatment for 
thromboembolic disorders, the use of NOACs instead of warfarin is probably associated with 
a reduction of non-pharmacologic health-care costs, since they offer reduced intracranial 
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haemorrhagic events and might improve overall quality of life. It is therefore evident that the 
increase of the initial economic expenses associated with NOACs must be addressed within 
a wider perspective. This evaluation should include medical consequences from both the 
clinical and the economic point of view, which is best achieved with cost-effective analysis. 
The cost-effectiveness of NOACs proved beneficial in a vast number of countries as 
reported in the previous section, which demands their wider uptake in clinical practice for 
patients deemed suitable. Absence of reversal agent for NOACs probably constitutes a 
barrier to their wider uptake, but reversal agents are being actively developed currently, with 
idarucizumab has been approved as reversal agent for dabigatran while andexanet alfa 
proves as reversal agent for anti-factor Xa NOACs [39].  
As previously discussed, patients receiving warfarin require close monitoring to ensure 
optimum anticoagulation and to minimise the risk of bleeding. This can be achieved in 
anticoagulation clinics that provide specialised care, consistent monitoring, and patient 
education, especially those managed by pharmacists. Pharmacists in the anticoagulation 
clinics usually work toward optimisation of warfarin therapy by ordering relevant laboratory 
tests, monitoring and maintaining target INR, recommending warfarin dose adjustment, 
reviewing concurrent medications, providing one-to-one patient education and working 
together with other relevant healthcare professionals [40,41]. Indeed, a systematic review 
and meta-analysis of studies that evaluated the effectiveness of pharmacist-participated 
warfarin therapy management reported significant reduction in total bleeding events [42]. 
Several other studies also demonstrated that pharmacist-participated warfarin therapy 
management led to a significant decrease in warfarin-related hospital admission [43], less 
frequency of drug interaction [44], a decrease in length of hospital stay [45], significant 
improvement in patient compliance [46,47], patient knowledge [48], and anticoagulation 
control [49]. Results from systematic review suggest that pharmacist-participated warfarin 
therapy management leads to economic benefit, as discussed beforehand.  
The dose requirements and the risk of over- or under-anticoagulation with warfarin therapy 
depend on many clinical and environment factors, including age as well as concurrent illness 
and medication. Nevertheless, genetic factors, which have been largely overlooked, are 
responsible for approximately 40% of the inter-individual variability in response in warfarin-
treated patients [50,51]. Polymorphisms in the VKORC1 gene, which codes for the 
pharmacodynamic target enzyme for warfarin, VKORC1, as well as CYP2C9 gene, which 
codes for the main metabolising enzyme of warfarin, CYP2C9, are associated with variability 
in dose requirements of warfarin [50,52-54]. Patients with a CYP2C9*2 or *3 allele variant 
with associated reduction in enzyme activity required lower warfarin dose compared to 
patients with a wild-type variant [55]. Variants in the VKORC1 allele were also found to be 
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playing a role in increased warfarin sensitivity [56]. While the initial dosing of warfarin is 
based on clinical characteristics currently, there are suggestions that genotyping the 
CYP2C9 and VKORC1 genes is useful for determining more appropriate initial dose and 
thereby increasing the effectiveness and safety of warfarin therapy. Therefore, several 
dosing algorithms have been proposed that incorporated both information on CYP2C9 and 
VKORC1 genotype as well as clinical factors, and expectation is that patients will achieve 
and maintain therapeutic INR range if such dosing algorithms are being utilised [51,57,58]. 
This could decrease the risk of adverse events, including stroke and bleeding, possibly 
leading to reduced medical costs. Nevertheless, due to heterogeneity in the results of the 
economic evaluations, no conclusive remarks could be drawn regarding the cost–
effectiveness of this strategy.  
5. Five-year view  
Evidence from the large and ever-growing body of economic literature about the cost-
effectiveness of oral anticoagulation therapies has shown that NOACs are cost-effective 
alternatives to warfarin. Despite increasing evidence on cost-effectiveness of NOACs, the 
uptake of this new therapeutic class into clinical practice has been slower than expected, 
especially due to factor related to absence of specific antidotes. Nevertheless, with 
introduction of idarucizumab as specific reversal agent for dabigatran and possible 
introduction of andexanet alfa as reversal agent for anti-factor Xa NOACs, the prescribing 
rate of NOACs is expected to increase. In addition, the entry of the generics of dabigatran 
following anticipated loss of United States, Japanese, and Canadian patent protection in 
2018 will certainly ease the financial pressure of health care system in funding NOACs, 
which should lead to wider uptake of NOACs in clinical practice in the future.  
Nevertheless, the cost-effectiveness of NOACs prescribing relative to pharmacist-
participated warfarin therapy management is unknown. Future economic evaluations should 
aim to resolve the question, since pharmacists have proved valuable in the management of 
warfarin therapy. While prescribing rate of NOACs is expected to rise, it would not eliminate 
the use of warfarin altogether since there are certain patient populations who would benefit 
from its use, especially those with compromised renal function and therefore contraindicate 
to the use of NOACs. Pharmacist-participated warfarin therapy management would certainly 
be helpful to these patient populations who could not take NOACs for any reason in which 
pharmacist-managed anticoagulation clinic would be expected to continue playing important 
roles in the coming years.  
On the other hand, conclusive evidence on the cost-effectiveness of pharmacogenetic-
guided dosing of warfarin is still impending, and future economic evaluation of this approach 
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is encouraged. It would also be interesting to look at the cost-effectiveness of the NOACs 
relative to pharmacogenetic-guided dosing of warfarin. With increasing appreciation towards 
precision medicine, genotype-guided dosing approach for warfarin therapy is promising for 
years to come.   
 
6. Key issues 
• Warfarin (vitamin K antagonist) is the widely available anticoagulant for human use, but it 
is associated with major concerns such as bleeding complications and the requirement 
for frequent monitoring. 
• Decades of research and development has produced promising alternatives to warfarin, 
namely, direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors (apixaban, 
edoxaban, rivaroxaban). 
• Initiation of warfarin therapy requires regular monitoring of the INR regardless of age to 
ensure its effectiveness and safety. The cost of performing one INR test varied from USD 
6.19 to USD 145.70. 
• Each NOAC was also proven to be at least as effective as warfarin when used in older 
patients, both in reduction of the risk of stroke and systemic embolism in atrial fibrillation 
as well as the risk of recurrent venous thromboembolism.  
• Many studies reported an increase in overall health-care costs with the use of NOACs, 
but the ICER was mostly below the reported willingness-to-pay threshold, indicating their 
cost-effectiveness.  
• The cost-effectiveness of pharmacist-participated warfarin therapy management was 
found to be either cost-saving or cost-effective. 
• Due to heterogeneity in the results of the economic evaluations, no definitive conclusions 
on the cost–effectiveness of genotype-guided dosing strategy can be drawn at this time. 
• The anticipated loss of United States, Japanese, and Canadian patent protection of 
dabigatran brand in 2018 should lead to wider uptake of NOACs in clinical practice in the 
future. 
• Due to limited number of studies assessing cost of managing complications and 
monitoring associated with NOACs, it is currently not possible to recommend which 
treatment can have more cost-saving effect. 
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